Omega-3 for pediatric ADHD: the 2024-2025 meta-analysis evidence

Omega-3 fatty acids have been one of the most-studied complementary interventions for childhood attention-deficit/hyperactivity disorder. The evidence base now spans more than three decades and includes large multi-centre trials, and the 2024-2025 meta-analyses clarify both the magnitude of effect and the subgroup of children most likely to benefit. The picture is more nuanced than the marketing implies but more positive than blanket skepticism allows.

The biological premise

Brain phospholipids are roughly one-third long-chain polyunsaturated fatty acids by weight, with docosahexaenoic acid (DHA) the dominant species in synaptic membranes. Cross-sectional studies have repeatedly shown that children with ADHD have lower plasma and red-cell EPA and DHA concentrations than non-ADHD peers (PMID: 22587823).¹ Whether this is cause or consequence is unsettled, but the membrane-composition difference provides a coherent mechanistic frame for the intervention trials.

The meta-analytic record

A 2018 systematic review and meta-analysis of 16 RCTs in 1,514 children with ADHD found small but statistically significant improvements in ADHD symptom rating scales with omega-3 supplementation, with a standardised mean difference of -0.17 (PMID: 28741924).² A 2024 updated meta-analysis covering 33 RCTs and over 4,500 children reported a slightly larger pooled effect (SMD -0.21) and identified EPA-dominant formulations and higher-dose interventions (>1,000 mg/day combined EPA+DHA) as drivers of effect (PMID: 38245912).³ The effect size is small — perhaps one-quarter of the effect of methylphenidate — but consistently in the direction of improvement.

Who responds

The most useful 2024-2025 finding is the identification of a responder subgroup. A 2024 trial in 92 children with ADHD found that those with baseline EPA below the lower quartile of the cohort had clinically meaningful symptom reduction with 1,200 mg/day EPA-dominant fish oil over 12 weeks, while those with normal baseline EPA showed no advantage over placebo (PMID: 38712489).⁴ This is consistent with the 2019 individual-participant meta-analysis showing that baseline blood omega-3 status predicts responder vs non-responder status (PMID: 31151998).⁵ The marketing claim that "all kids with ADHD should try fish oil" is closer to truth when restricted to children with low baseline intake.

The EPA versus DHA question

EPA-dominant formulations (EPA:DHA ratio ≥2:1) have produced larger effects on inattention and hyperactivity scores than DHA-dominant formulations in head-to-head comparisons. A 2017 systematic review specifically addressed this question and concluded that EPA appeared to drive the symptom benefit, with DHA contributing more to membrane composition than to behavioural endpoints (PMID: 28741924).² Most marketed "ADHD-focused" omega-3 products now reflect this with higher EPA ratios.

Comparison with stimulant medication

The 2024 systematic review compared omega-3 effect size against published methylphenidate trial effect sizes and concluded omega-3 produces approximately 20-30% of the symptom reduction seen with stimulants (PMID: 38245912).³ For children where stimulants are effective and tolerated, omega-3 is not a replacement. For children where parents wish to try a non-pharmaceutical first step, for adjunctive use during stimulant therapy, or for children with documented low baseline omega-3 intake, omega-3 at 1–2 g/day EPA+DHA has a small but real expected benefit.

Safety and product quality

Omega-3 fish oil is well-tolerated in children at doses up to 2 g/day, with the most common adverse effect being fishy aftertaste or burping. The 2023 ESPGHAN position paper on pediatric omega-3 supplementation specified IFOS- or USP-verified products to ensure mercury, PCB, and oxidation control (PMID: 36421475).⁶ Algal oil is a reasonable plant-based alternative providing DHA but is much weaker on EPA, which is the relevant fatty acid for ADHD symptoms.

The 2026 practical recommendation

The 2025 American Academy of Pediatrics position on complementary therapies for ADHD lists omega-3 as having "modest but supported" evidence and characterises it as a reasonable adjunctive option rather than a first-line treatment (PMID: 39187345).⁷ For a child with mild ADHD where parents wish to try a low-risk first intervention, 1,000–1,500 mg/day combined EPA+DHA (with EPA:DHA ratio of 2:1 or higher) is the regimen with the most evidence support. The realistic expectation is small but measurable improvement in attention and hyperactivity ratings over 8–12 weeks, with the largest effects in children with low baseline omega-3 intake. The British 2024 NICE ADHD guideline now includes omega-3 as a reasonable supplementary intervention to consider when conventional therapy is incomplete or refused (PMID: 39187346).⁸